
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Check price for EmbodyOn Embody's site · partner link
Comparison · updated November 3, 2026
Embody is our starting recommendation for a cash-paying reader who wants a compounded injection and a clearly priced one-month option.

Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Check price for EmbodyOn Embody's site · partner link
First month; refill interval to confirm · confirm the full bill
Check price for MEDVi (affiliate link)On MEDVi's site · partner link
These two prices are different kinds of bill, so read the line under each price before you compare them.
Both providers pay us a commission through our links. Our recommendation reflects the needs described here; commissions do not set scores. How we make money
This content was researched and written with AI assistance. MEDVi referral links are affiliate links: we may earn a commission if you sign up. This is independent information, not medical advice or a clinical review.
Embody is our starting recommendation for a cash-paying reader who wants a compounded injection and a clearly priced one-month option. Its public semaglutide catalogue plan is $79 with medication included. MEDVi is worth exploring when treatment format matters more: it lists oral and injectable routes. Our choice comes down to the prescribed product, the ongoing bill and the care you want. The detailed sections below explain MEDVi's dated price and regulatory records so you can make that choice with context.
Our pick for a simple cash-pay injection plan
Medication, clinical review, coaching and shipping in one plan. Start with one month if you want a smaller initial commitment.
Semaglutide: $79 for one month; the October 27 catalogue also listed $588 prepaid for a year ($49/month equivalent) in a sale advertised through December 1, 2026. Compounded treatment requires clinical approval and is not FDA approved.
Choose MEDVi to explore more treatment formats
MEDVi lists injection and oral treatment routes. It is worth comparing if the way you take medication is central to your decision.
Compare the prescribed product and ongoing total. Compounded tablets are not FDA-approved pills; the dated regulatory record is explained below.
Sources: Embody catalogue and payment terms · Medvi program
| Embody | MEDVi | |
|---|---|---|
| Price | from $49/mo | $99(affiliate link)First month, then $199 per refill; confirm the refill interval |
| Medicine | Compounded only | Brand-name and compounded |
| Needle-free option | Not listed | Yes, a pill or other oral form |
| Insurance | BothNo insurance listed | |
| Consultation | BothIncluded | |
| Shipping | BothFree | |
| Where it ships | 49 states plus DC, all except Louisiana | Not published |
| Trustpilot | 3.8 / 5 across 10,100 reviews | 4.3 / 5 across 15,014 reviews |
| BBB rating | D+ (not accredited) | F (not accredited) |
| Our score | 7.6/10 Good | 7.2/10 Good |
| Assessment limits | BothChecked Oct 16, 2026; a rating claim didn't match Trustpilot. | |
Four published plan lengths for each injection. A sale advertised October 27 through December 1, 2026 cut the twelve-month prepaid amounts to $588 for semaglutide and $1,188 for tirzepatide; one-month plans stayed at $79 and $129.
Payments are normally non-refundable; a limited medical-disqualification exception applies.
The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.
We checked Embody's prices on October 27, 2026.Every Embody price and plan
Embody’s GLP-1 website is joinem.co. GLP-1 Picks is an independent comparison site.
Want Embody on its own? Read our Embody GLP-1 review to see what you pay for semaglutide or tirzepatide and what customer reviews say, or check is Embody legit for its BBB, Trustpilot and FDA records.
Compounded semaglutide tablets and injections, a separate compounded tirzepatide injection, and brand-name Wegovy and Zepbound paths with a $99 membership plus medication.
First month: $99 for compounded semaglutide injection with no contract, then $199 per refill. The landing page does not state the refill interval; MEDVi's April to August 2026 replies to BBB complaints described 28-day renewals. Confirm the interval and next charge. No verified annual payment count.
We checked MEDVi's prices on November 3, 2026.
Embody's public catalogue lists compounded semaglutide at $79 for one month and tirzepatide at $129, with lower monthly equivalents on longer prepaid terms. Its yearly-plan sale, advertised October 27 through December 1, 2026, was $588 prepaid for semaglutide or $1,188 for tirzepatide, equivalent to $49 or $99 per month. Confirm current and renewal terms. MEDVi's landing page, checked November 3, 2026, lists compounded semaglutide at $99 for the first month with no contract and $199 per refill, without stating the refill interval. For the first month of semaglutide injections, Embody lists $79 on its one-month plan and MEDVi lists $99. The $49 annual-plan sale equivalent, advertised through December 1, 2026, required $588 upfront; MEDVi's $199 refill price has no stated interval, so it does not establish a comparable recurring monthly cost.
The trade-off is choice. Embody's September 3 catalogue lists compounded semaglutide and tirzepatide injections; its former oral tirzepatide gum is absent. MEDVi lists compounded semaglutide injections and dissolvable tablets, plus a separate compounded tirzepatide injection on its dedicated page checked October 8, 2026. That compounded offer's full commitment and renewal terms remain unconfirmed; the $99/$199 semaglutide schedule is not its price. Branded Zepbound is another distinct path: its listed $99 membership excludes medication and is not a complete treatment price.
Sources:Embody published product catalogue· Current MEDVi offer (affiliate link)(affiliate link)· MEDVi injection costs and pharmacy details· MEDVi compounded tirzepatide source
MEDVi offers more ways to take treatment. It lists oral tablets and injections for compounded GLP-1 care, while Embody's September 3 catalogue lists injections only; its former tirzepatide gum is absent. Both now name pharmacy partners: MEDVi lists RedRock Pharmacy, Beaker Pharmacy & Compounding and Triad Rx; Embody lists Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx.
The dated Trustpilot readings differ: MEDVi showed 4.3/5 across 15,014 reviews on October 15, 2026, while Embody showed 3.8/5 across 10,100 on October 17. Embody's profile includes merged reviews. Do not treat either rating as clinical-quality evidence. MEDVi had an unaccredited F rating at the BBB with 763 complaints in three years on October 15. Embody's shared operator showed D+, not accredited, with 245 company-wide complaints on October 17; the profile also lists SnagRx and RodeoMeds as alternate names. That total is neither Embody-only nor a count of unresolved cases.
Sources:MEDVi on Trustpilot· MEDVi pharmacy terms· MEDVi at the BBB· Embody on Trustpilot· Embody's shared operator at the BBB
The FDA issued warning letter #721455 to MEDVi on February 20, 2026. The agency says MEDVi-branded labels implied MEDVi compounded the products when it did not, and that website comparisons implied compounded semaglutide and tirzepatide were equivalent to or FDA-evaluated like approved brands. This is a misbranding and marketing action, not an allegation that the medication was unsafe.
Our published rubric shows the FDA warning letter as a dated alert alongside the score word. FDA's database still showed no response or close-out letter for MEDVi on October 16, 2026. MEDVi's current score is 7.2 out of 10, including certification verified directly with LegitScript on October 21; the broader criterion assessment remains dated October 16. Certification does not resolve the FDA warning letter. MEDVi gets no scoring exception because it is an affiliate partner.
Sources:FDA warning letter #721455· LegitScript certification for medvi.org· Our scoring methodology
Strengths
More to watch for
Strengths
More to watch for
Compounded medicines are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold. Read the FDA's explanation of the risks.
Embody publishes the lower starting rates: compounded semaglutide from $79 for one month (its $49/mo yearly-plan sale was advertised through December 1, 2026) and GLP-1 + GIP injections from $129/mo, compared with MEDVi's $99 semaglutide first month and $199 refills, whose interval MEDVi's landing page does not state.
MEDVi rates higher on Trustpilot (4.3 against Embody's 3.8 out of 5), but neither company is accredited at the BBB: MEDVi has an F, and Embody's parent company, which also runs SnagRx and RodeoMeds, a D+.
We cannot prove one provider's medication is safer from public records alone.
Consider Embody first if the lower advertised plan rate fits your medication and commitment.
Embody:prices checked October 27, 2026, score evidence assessed October 16, 2026.Read our Embody review
MEDVi:prices checked November 3, 2026, score evidence assessed October 16, 2026.Read our MEDVi review
We score on a published methodology, and partnership never changes a score or a fact here.
Before you sign up, read our trust checks: is Embody legit and is MEDVi legit.